ABSTRACT
Background Dietary restriction (DR) is gaining ground as a means to prevent and treat a range of conditions and diseases. In our study we address the impact of periodic abstinence from animal products (periodic veganism) on markers of health.
Methods We profiled 200 periodic vegan (PV) individuals who switch between an omnivorous and a vegan diet, abstaining for 180-200 days annually, in a highly structured manner. We also profiled 211 non-vegan (NV), omnivorous individuals. Traits were measured at two timepoints, the first capturing a period of omnivory for both groups, the second capturing a period during which PV individuals only had followed a vegan diet for three to four weeks. We report results on blood lipids (total, LDL, and HDL cholesterol, triglycerides), glucose metabolism (glucose, insulin, HBA1c), renal function (urea, uric acid, creatinine), liver function (AST, ALT, γ-GT), bone/liver function (ALP), thyroid function (TSH), inflammation (CRP), complete blood counts, anthropometric traits and blood pressure.
Results Upon DR, PV individuals display decreased levels of total and LDL cholesterol [both β=-0.3, 95% CI:(-0.4, -0.2) mmol/L] and of CRP [β=-1.3, 95% CI:(-2.1, -0.5) mg/L] which drops by 28%. Compared to NV, PV individuals display consistently lower counts of total white blood cells (WBC) [β=-0.4, 95% C.I:(-0.6,-0.3) K/μL] and neutrophils [β=-0.4, 95% C.I:(-0.5,-0.2) ×103/μl], but higher levels of ALP [β=5.9, 95% C.I:(2.7,9.1) U/L], suggesting detrimental effects on bone health.
Conclusion Harnessing dietary intake to prevent and treat disease is a promising approach that should also be explored for synergies with pharmacological therapies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The FastBio study was supported through a European Research Council Grant to Antigone Dimas (FastBio 716998)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The FastBio study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the BSRC Alexander Fleming Bioethics Committee (17-02-2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available from the corresponding author on reasonable request
